![[Valid RSS]](images/valid-rss-rogers.png "Valid RSS")
This is a valid RSS feed.
This feed is valid, but interoperability with the widest range of feed readers could be improved by implementing the following recommendations.
<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:wfw="http://wellformedweb.org/CommentAPI/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:sy="http://purl.org/rss/1.0/modules/syndication/" xmlns:slash="http://purl.org/rss/1.0/modules/slash/" xmlns:media="http://search.yahoo.com/mrss/" > <channel> <title>International Biopharmaceutical Industry</title> <atom:link href="https://international-biopharma.com/feed/" rel="self" type="application/rss+xml" /> <link>https://international-biopharma.com</link> <description>Supporting Modern Science Through Communication</description> <lastBuildDate>Wed, 10 Sep 2025 15:29:19 +0000</lastBuildDate> <language>en-GB</language> <sy:updatePeriod> hourly </sy:updatePeriod> <sy:updateFrequency> 1 </sy:updateFrequency> <generator>https://wordpress.org/?v=6.8.2</generator> <image> <url>https://international-biopharma.com/wp-content/uploads/2021/03/IBI-150x150.jpg</url> <title>International Biopharmaceutical Industry</title> <link>https://international-biopharma.com</link> <width>32</width> <height>32</height></image> <item> <title>Gilead Sciences Commits to Veeva Vault CRM</title> <link>https://international-biopharma.com/gilead-sciences-commits-to-veeva-vault-crm/</link> <dc:creator><![CDATA[Alice Phillips]]></dc:creator> <pubDate>Wed, 10 Sep 2025 15:28:59 +0000</pubDate> <category><![CDATA[news]]></category> <guid isPermaLink="false">https://international-biopharma.com/?p=18004</guid> <description><![CDATA[Next generation CRM with deep capabilities and agentic AI Veeva Systems (NYSE: VEEV) today announced that Gilead Sciences has committed to Veeva Vault CRM. “Gilead is a leader in life changing medicines and has been a pioneer of major scientific advancements in virology, inflammation, and oncology,” said Veeva CEO Peter Gassner. “We are honored to be a […]]]></description> <content:encoded><![CDATA[<p><em>Next generation CRM with deep capabilities and agentic AI</em></p> <p></p> <p></p> <p><a href="https://www.veeva.com/" target="_blank" rel="noreferrer noopener">Veeva Systems</a> (NYSE: VEEV) today announced that Gilead Sciences has committed to <a href="https://www.veeva.com/products/crm-suite/crm/" target="_blank" rel="noreferrer noopener">Veeva Vault CRM.</a></p> <p>“Gilead is a leader in life changing medicines and has been a pioneer of major scientific advancements in virology, inflammation, and oncology,” said Veeva CEO Peter Gassner. “We are honored to be a strategic partner to Gilead and extend that partnership to Vault CRM.”</p> <p>“We are excited to expand our long-standing partnership with Veeva by moving to Vault CRM,” said Anna Åsberg, global CIO at Gilead Sciences. “We share a deep commitment to advancing medicine and are excited to explore the potential of Veeva AI to help drive commercial execution to the next level.”</p> <p>Vault CRM is part of the Vault CRM Suite of applications that provides the foundation for commercial execution. Veeva AI for Vault CRM delivers multiple AI agents, including pre-call planning, compliant free text, and voice control, to drive commercial efficiency and effectiveness.</p> <p><strong>About Veeva Systems<a></a></strong></p> <p>Veeva delivers the industry cloud for life sciences with software, data, and business consulting. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,500 customers, ranging from the world’s largest biopharmaceutical companies to emerging biotechs. As a <a href="https://www.veeva.com/pbc/" target="_blank" rel="noreferrer noopener">Public Benefit Corporation</a>, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit <a href="http://veeva.com/" target="_blank" rel="noreferrer noopener">veeva.com</a>.</p> <p><strong>About Gilead Sciences<br></strong>Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, cancer and inflammation. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California.</p> <p><strong>Veeva Forward-Looking Statements</strong></p> <p>This release contains forward-looking statements regarding Veeva’s products and services and the expected results or benefits from use of our products and services. These statements are based on our current expectations. Actual results could differ materially from those provided in this release and we have no obligation to update such statements. There are numerous risks that have the potential to negatively impact our results, including the risks and uncertainties disclosed in our filing on Form 10-Q for the period ended July 31, 2025, which you can find <em><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1393052/000139305225000067/veev-20250731.htm#i7e129a0ad48d459ea13c21cd7e2de073_124" target="_blank" rel="noreferrer noopener">here</a></em> (a summary of risks which may impact our business can be found on pages 33 and 34), and in our subsequent SEC filings, which you can access at <em><a href="https://www.sec.gov/" target="_blank" rel="noreferrer noopener">sec.gov</a></em>.</p>]]></content:encoded> </item> <item> <title>Symeres acquires DGr Pharma to enhance regulatory expertise and broaden its biopharma capabilities</title> <link>https://international-biopharma.com/symeres-acquires-dgr-pharma-to-enhance-regulatory-expertise-and-broaden-its-biopharma-capabilities/</link> <dc:creator><![CDATA[Alice Phillips]]></dc:creator> <pubDate>Wed, 10 Sep 2025 11:49:22 +0000</pubDate> <category><![CDATA[news]]></category> <guid isPermaLink="false">https://international-biopharma.com/?p=18002</guid> <description><![CDATA[Symeres, a leading global Contract Research, Development and Manufacturing Organisation (CRDMO), announces the acquisition of DGr Pharma, a drug development-focused consultancy, to expand its integrated early-stage drug development services and accelerate IND-enabling capabilities for biopharma clients. The acquisition is supported by Keensight Capital (“Keensight”), one of the leading private equity managers dedicated to pan-European Growth […]]]></description> <content:encoded><![CDATA[<p></p> <p><strong>Symeres, a leading global Contract Research, Development and Manufacturing Organisation (CRDMO), announces the acquisition of DGr Pharma, a drug development-focused consultancy, to expand its integrated early-stage drug development services and accelerate IND-enabling capabilities for biopharma clients. The acquisition is supported by Keensight Capital (“Keensight”), one of the leading private equity managers dedicated to pan-European Growth Buyout<sup>[1]</sup> investments.</strong></p> <p>Founded in 2018 and based in the Netherlands, DGr Pharma specialises in pre-clinical and clinical regulatory strategy and consultancy for biotech and pharmaceutical partners working in early drug development. Its core services include chemical-pharmaceutical, non-clinical and clinical development planning, quality assurance, and regulatory submissions. DGr Pharma has deep expertise in small and large molecules, including antibodies, ADCs and oligonucleotides. With a reputation for scientific rigour, DGr Pharma adds significant regulatory depth to the Symeres portfolio, enabling it to deliver a more integrated solution across the full spectrum of drug discovery and development.</p> <p>DGr Pharma’s pharmacokinetic data analysis services operate under Good Clinical Pratice (GCP) and Good Laboratory Practice (GLP), expertise that aligns with Symeres’ integrated offering, including ADME. The GLP status enhances data quality and regulatory readiness, giving Symeres’ clients a more efficient and reliable path to IND submission.</p> <p>Guillaume Jetten, CEO of Symeres, commented: “<em>This acquisition strengthens our ability to offer truly integrated solutions across the drug discovery and development spectrum. DGr Pharma’s expertise enhances our scientific capabilities, allowing us to better support our clients’ evolving needs and reinforce Symeres’ position as a partner of choice in the global biopharma market.”</em></p> <p>Kees Groen, Founder and CEO of DGr Pharma, added<em>: “This is an exciting new chapter for DGr Pharma. Joining Symeres provides us with the opportunity to grow our reach and expand the value we bring to clients, particularly in early-stage development. We share Symeres’ commitment to high-quality science, long-term relationships and entrepreneurial ambition and we look forward to being part of the next phase of growth.”</em></p> <p>Amit Karna, Partner at Keensight Capital, concluded: <em>“We are proud to support Symeres with this specialized acquisition, which will extend the company’s capabilities into highly complementary services and attractive drug classes. We look forward to continuing to support the Symeres team as they selectively broaden the Company’s offering for their blue-chip biopharma clients.””</em></p> <p><a id="_ftn1" href="#_ftnref1"></a><sup>[1] </sup><strong><em>Growth Buyout:</em></strong><em> investment in profitable, private companies experiencing strong growth, in minority or majority positions, with or without leverage, using a flexible approach tailored to the needs of individual entrepreneurs, in order to finance organic growth projects, acquisition strategies or provide historic shareholders with liquidity.</em></p>]]></content:encoded> </item> <item> <title>Abselion Launches AAVX and AAV9 Total Capsid Quantification Kits</title> <link>https://international-biopharma.com/abselion-launches-aavx-and-aav9-total-capsid-quantification-kits/</link> <dc:creator><![CDATA[Alice Phillips]]></dc:creator> <pubDate>Tue, 09 Sep 2025 08:56:43 +0000</pubDate> <category><![CDATA[news]]></category> <guid isPermaLink="false">https://international-biopharma.com/?p=18000</guid> <description><![CDATA[● Ready-to-use solution for Amperia benchtop platform supports rapid, reliable quantification across a range of serotypes ● Kits incorporate Thermo Fisher Scientific’s CaptureSelect affinity reagents for enhanced specificity and consistency Abselion, a pioneering life sciences technology company focused on simplifying biomolecule quantification, has expanded its product offering with the launch of the AAVX Total Capsid Quantification Kit […]]]></description> <content:encoded><![CDATA[<p></p> <p>● <em>Ready-to-use solution for Amperia benchtop platform supports rapid, reliable quantification across a range of serotypes</em></p> <p>● <em>Kits incorporate Thermo Fisher Scientific’s CaptureSelect affinity reagents for enhanced specificity and consistency</em></p> <p>Abselion, a pioneering life sciences technology company focused on simplifying biomolecule quantification, has expanded its product offering with the launch of the AAVX Total Capsid Quantification Kit and the AAV9 Total Capsid Quantification Kit. Both kits are designed for use with its <a href="https://www.abselion.com/amperia/" target="_blank" rel="noreferrer noopener">Amperia</a><img src="https://s.w.org/images/core/emoji/16.0.1/72x72/2122.png" alt="™" class="wp-smiley" style="height: 1em; max-height: 1em;" /> benchtop quantification platform and include Thermo Fisher Scientific’s CaptureSelect<img src="https://s.w.org/images/core/emoji/16.0.1/72x72/2122.png" alt="™" class="wp-smiley" style="height: 1em; max-height: 1em;" /> affinity reagents. Combining these trusted reagents with Abselion’s consistent assay format reduces the need for in-house optimisation. These kits offer researchers working in adeno-associated virus (AAV) development and characterisation a more streamlined and accessible workflow to generate reproducible titre measurements across a broad range of serotypes and process conditions.</p> <p>Abselion’s Amperia benchtop platform is a simple-to-use solution for rapid and accurate automated quantification of a range of biomolecules, without optics, fluidics, or specialist training. Each kit is supplied in a ready-to-use format, including sensor strips, assay plates, matched detection reagents, and assay buffers for the binding and detection steps. The expanded kit range enhances the utility of Amperia for scientists working across gene therapy development and process workflows, offering a practical, dependable approach to total capsid quantification from purified or complex samples.<s></s></p> <p>Abselion has entered into a licensing agreement with Thermo Fisher Scientific to incorporate CaptureSelect affinity reagents into its AAV quantification kits. CaptureSelect technology is based on recombinant single-domain antibodies designed for high target specificity, low cross-reactivity, and consistent batch performance to ensure robust titre quantification. With the integration of these reagents, the new kits advance Abselion’s AAV assay format, bringing improved performance and broader serotype applicability.</p> <p>Both kits use a sandwich-style immunoassay format, in which biotin- and HRP-conjugated CaptureSelect antibodies are sequentially applied to bind AAV capsids. The resulting signal is detected electrochemically using Amperia sensor strips, enabling accurate quantitative detection across a range of AAV sample types and concentrations.</p> <p>The AAVX Total Capsid Quantification Kit includes CaptureSelect Anti-AAVX Biotin and HRP Conjugates, enabling broad serotype coverage including AAV1–8 and AAVrh10. The AAV9 Total Capsid Quantification Kit incorporates CaptureSelect Anti-AAV9 Biotin and HRP Conjugates for focused quantification of AAV9 particles.</p> <p><strong>Dr Ruizhi Wang, CEO and Founder, Abselion, said:</strong> <em>“Reliable quantification of total AAV capsid concentration is key to maintaining consistency and supporting informed decision-making. The integration of Thermo Fisher Scientific’s CaptureSelect reagents strengthens the performance of Abselion’s AAV kits and reflects our focus on making high-quality titre measurement simpler and more accessible. With these additions, Amperia offers researchers a ready-to-use solution that</em> <em>combines trusted reagent technologies with a streamlined assay format, enabling reliable quantification across a wider range of serotypes and development workflows</em>.”</p> <p><strong>Dr Kelly Flook, Sr. Manager, Product Management</strong><strong>,</strong> <strong>Pharma Analytics</strong><strong>, Thermo Fisher Scientific, said: </strong><em>“</em><em>CaptureSelect affinity reagents are designed to deliver high specificity and lot-to-lot consistency, making them well suited for applications such as AAV capsid quantification. We’re pleased that Abselion has incorporated these reagents under licence to support their assay kits for the Amperia platform</em><em>.”</em></p> <p>For further information about Abselion’s AAVX and AAV9 Total Capsid Quantification Kits, please visit: <a href="https://www.abselion.com/assay-kits/" target="_blank" rel="noreferrer noopener">https://www.abselion.com/assay-kits/</a> or download the application note “<a href="https://www.abselion.com/application-note-aav-gene-therapy/" target="_blank" rel="noreferrer noopener">Empowering AAV Quantification for Gene Therapy Research</a>”. The Abselion team will also be attending <a href="https://www.terrapinn.com/conference/festival-of-biologics/index.stm" target="_blank" rel="noreferrer noopener">Festival of Biologics</a> (30 Sep–02 Oct in Basel, Switzerland). Meet the team at booth 240 to learn more.</p>]]></content:encoded> </item> <item> <title>BioPharma Deals – The Survival Series</title> <link>https://international-biopharma.com/biopharma-deals-the-survival-series/</link> <dc:creator><![CDATA[Alice Phillips]]></dc:creator> <pubDate>Mon, 08 Sep 2025 14:51:15 +0000</pubDate> <category><![CDATA[Events]]></category> <guid isPermaLink="false">https://international-biopharma.com/?p=17993</guid> <description><![CDATA[📆 24 – 25 November, 2025 📍 Hilton Munich Airport, Terminalstraße Mitte 20, 85356 München-Flughafen, Germany Description BioPharma Deals: The Survival Series is a new kind of event, a high-impact conference built for companies navigating today’s funding drought by partnering smarter, earlier, and more creatively. We bring together biotech, pharma, investors, and advisors to explore practical […]]]></description> <content:encoded><![CDATA[<p></p> <p><img src="https://s.w.org/images/core/emoji/16.0.1/72x72/1f4c6.png" alt="📆" class="wp-smiley" style="height: 1em; max-height: 1em;" /> 24 – 25 November, 2025</p> <p><img src="https://s.w.org/images/core/emoji/16.0.1/72x72/1f4cd.png" alt="📍" class="wp-smiley" style="height: 1em; max-height: 1em;" /> <strong>Hilton Munich Airport,</strong></p> <p>Terminalstraße Mitte 20, 85356 München-Flughafen, Germany</p> <p><strong>Description</strong></p> <p>BioPharma Deals: The Survival Series is a new kind of event, a high-impact conference built for companies navigating today’s funding drought by partnering smarter, earlier, and more creatively. We bring together biotech, pharma, investors, and advisors to explore practical pathways to collaboration when traditional funding sources have slowed.</p> <p>Forget generic discussions. This is a conference for those on the front lines, dealmakers, BD&L teams, and executives, solving real problems with real partnerships.</p> <p>If you’re seeking licensing, M&A, risk-sharing alliances, or alternative routes to capital and commercialisation, this is where you meet the people and ideas that can move you forward.</p> <p><img src="https://s.w.org/images/core/emoji/16.0.1/72x72/1f310.png" alt="🌐" class="wp-smiley" style="height: 1em; max-height: 1em;" /> <a href="https://biopharmadeals.com/index.html" target="_blank" rel="noreferrer noopener">https://biopharmadeals.com/index.html</a></p> <p><img src="https://s.w.org/images/core/emoji/16.0.1/72x72/1f517.png" alt="🔗" class="wp-smiley" style="height: 1em; max-height: 1em;" /><a href="https://biopharmadeals.com/registration.html" target="_blank" rel="noreferrer noopener">https://biopharmadeals.com/registration.html</a></p> <p><img src="https://s.w.org/images/core/emoji/16.0.1/72x72/1f4e7.png" alt="📧" class="wp-smiley" style="height: 1em; max-height: 1em;" /> <a href="mailto:kelly@biopharmadeals.com">kelly@biopharmadeals.com</a></p>]]></content:encoded> </item> <item> <title>CPHI Frankfurt 2025 to welcome more than 60,000 pharma professionals as the global event returns to Germany</title> <link>https://international-biopharma.com/cphi-frankfurt-2025-to-welcome-more-than-60000-pharma-professionals-as-the-global-event-returns-to-germany/</link> <dc:creator><![CDATA[Alice Phillips]]></dc:creator> <pubDate>Mon, 08 Sep 2025 13:37:08 +0000</pubDate> <category><![CDATA[news]]></category> <guid isPermaLink="false">https://international-biopharma.com/?p=17990</guid> <description><![CDATA[Informa Markets will once again welcome the global pharmaceutical industry to CPHI Frankfurt 2025, running from October 28 to 30 at Messe Frankfurt. The three-day event is expected to draw more than 63,000 attendees, with six content theatres, more than 2,000 exhibitors, and a packed programme dedicated to networking and innovation. Celebrating its 36th year, CPHI […]]]></description> <content:encoded><![CDATA[<p></p> <p>Informa Markets will once again welcome the global pharmaceutical industry to<a href="https://tracking.us.nylas.com/l/6827a31313234cee9654bc63027cab72/0/0cbe42738f75f5c0feea5222ef7cf99da49f0aacca5bd440a7020922ea95e5b4?cache_buster=1757334175" target="_blank" rel="noreferrer noopener"> </a><a href="https://tracking.us.nylas.com/l/6827a31313234cee9654bc63027cab72/1/a08670b56daf561e9f028a5cf72dc7597855bc6a258c888fbdb97e44a7863a47?cache_buster=1757334175" target="_blank" rel="noreferrer noopener">CPHI Frankfurt 2025</a>, running from October 28 to 30 at Messe Frankfurt. The three-day event is expected to draw more than 63,000 attendees, with six content theatres, more than 2,000 exhibitors, and a packed programme dedicated to networking and innovation.</p> <p>Celebrating its 36th year, CPHI Frankfurt remains the largest and most influential pharmaceutical event globally, bringing together professionals from across the drug development and manufacturing ecosystem. The event is organised by Informa Markets, a division of Informa PLC, which delivers B2B events across global industries.</p> <p>“CPHI is more than an event, it’s a global experience,” said Tara Dougal, event director, CPHI Frankfurt. “It’s the one place each year where the full pharmaceutical supply chain comes together to collaborate, build relationships, and get business done.”</p> <p>Following a record-setting 2024 event in Milan that drew 59,000 attendees, this year’s event aims to surpass that benchmark. In recent years, CPHI has expanded its content and exhibitor zones to reflect industry diversification, adding bioproduction, finished dosage formulation, drug delivery, and packaging alongside its traditional strength in APIs.</p> <p>In response to continued market growth and emerging industry trends, CPHI Frankfurt 2025 will introduce several new feature zones aimed at supporting innovation, diversification, and deeper sector engagement. These zones will spotlight areas such as digital health technologies, AI-powered drug development, and sustainable pharma manufacturing, reflecting the industry’s evolving priorities and creating new opportunities for exhibitors and attendees alike.</p> <p>“The new zones are designed to keep pace with where the market is going,” said Dougal. “They’re a direct response to rising demand from both attendees and exhibitors for more focused, future-looking areas within the show.”</p> <p>Attendees can also access a robust line-up of features that enhance both business outcomes and professional development:</p> <p>● Six content theatres, running across all three days, offering insight into market trends, R&D, manufacturing, and regulation.<br></p> <p>● The CPHI Awards and Celebration, recognising innovation and leadership across 14 categories, including Women in Pharma and Future Leader of the Year.<br></p> <p>● Happy hour networking events on days one and two, designed to foster informal connections.<br></p> <p>● An event planner app with agenda-building and real-time floor navigation features, remaining active post-show to support follow-up.<br></p> <p>“Whether you’re a first-time attendee or a returning exhibitor, planning is key,” Dougal said. “Our digital platform helps attendees get the most value by pre-booking meetings, building agendas, and navigating efficiently on site.”</p> <p>The CPHI portfolio includes 10 international events spanning Europe, the Americas, the Middle East, and Asia. The newest addition, CPHI Middle East, launched in Riyadh in 2024 and will return in April 2026.</p> <p><strong>About Informa Markets</strong></p> <p>Informa Markets creates platforms for industries and specialist markets to trade, innovate, and grow. As part of Informa PLC, it delivers more than 450 B2B events annually across key sectors including healthcare, life sciences, construction, and fashion. The company’s mission is to foster global communities, enabling meaningful connections and commercial success.</p> <p>To learn more about CPHI Frankfurt, visit the website <a href="https://tracking.us.nylas.com/l/6827a31313234cee9654bc63027cab72/2/af0271481bb8f22715e144317bb897ec8c9b84fba7358ddd2eacd70eea54c56b?cache_buster=1757334175" target="_blank" rel="noreferrer noopener">here</a></p> <p><strong>Media Contact:</strong></p> <p>Aranda Rahbarkouhi<br>ramarketing<br><a href="https://tracking.us.nylas.com/l/6827a31313234cee9654bc63027cab72/3/88cb56db523a945c4052444421f1b2b13a5608c05421cf18ca6923dfbacfded9?cache_buster=1757334175" target="_blank" rel="noreferrer noopener">aranda@ramarketingpr.com</a></p>]]></content:encoded> </item> <item> <title>GOVERNOR MURPHY INAUGURATES NEW US CONTINUOUS BIOMANUFACTURING FACILITY OF INDIA-BASED ENZENE</title> <link>https://international-biopharma.com/governor-murphy-inaugurates-new-us-continuous-biomanufacturing-facility-of-india-based-enzene/</link> <dc:creator><![CDATA[Alice Phillips]]></dc:creator> <pubDate>Fri, 05 Sep 2025 11:03:50 +0000</pubDate> <category><![CDATA[news]]></category> <guid isPermaLink="false">https://international-biopharma.com/?p=17977</guid> <description><![CDATA[Governor Phil Murphy yesterday officially inaugurated the state-of-the-art biomanufacturing facility of Enzene, a leading global continuously innovative development and manufacturing organization (CIDMO), marking a significant milestone in the expansion of global biotech capabilities in the United States. Located in Hopewell, the new 80,000-sq.-ft. facility represents Enzene’s first major manufacturing investment in the U.S., reinforcing its […]]]></description> <content:encoded><![CDATA[<p></p> <p>Governor Phil Murphy yesterday officially inaugurated the state-of-the-art biomanufacturing facility of Enzene, a leading global continuously innovative development and manufacturing organization (CIDMO), marking a significant milestone in the expansion of global biotech capabilities in the United States.</p> <p>Located in Hopewell, the new 80,000-sq.-ft. facility represents Enzene’s first major manufacturing investment in the U.S., reinforcing its commitment to supporting pharmaceutical innovation and supply chain resilience across North America. As well as fed-batch drug substance manufacturing, the site makes extensive use of the company’s modular EnzeneX<img src="https://s.w.org/images/core/emoji/16.0.1/72x72/2122.png" alt="™" class="wp-smiley" style="height: 1em; max-height: 1em;" /> 2.0 platform, which is the world’s first fully-connected continuous manufacturing<img src="https://s.w.org/images/core/emoji/16.0.1/72x72/2122.png" alt="™" class="wp-smiley" style="height: 1em; max-height: 1em;" /> (FCCM<img src="https://s.w.org/images/core/emoji/16.0.1/72x72/2122.png" alt="™" class="wp-smiley" style="height: 1em; max-height: 1em;" />) technology. The innovative platform is sustainable and scalable, and leverages optimized cell media and process analytical technology (PAT) to achieve 10-times the yield of conventional biomanufacturing and reduce the cost of goods sold (COGS) to as low as $40 per gram.</p> <p>“When Enzene — one of India’s most promising biotechnological companies — decided to launch its very first U.S. manufacturing base, they knew there was nowhere better to do it than right here in New Jersey. Their decision reflects not only our state’s strength as a hub for global business and innovation, but also the deep cultural ties that bind New Jersey and India,” said Governor Phil Murphy.<strong> </strong>“This state-of-the-art facility represents the future of advanced manufacturing — ultimately creating hundreds of jobs and generating $50 million in investment. As Enzene expands its presence here in New Jersey, we remain committed to supporting the company as it builds the world-class manufacturing ecosystem of tomorrow.”</p> <p>“We are proud to bring our global expertise to the U.S. and contribute to the advancement of biopharmaceutical manufacturing,” added Himanshu Gadgil, Ph.D., CEO of Enzene. “Our first-to-market manufacturing technology is forging a new path in biologics manufacturing that will provide a cost-efficient, high yield, U.S.-based biomanufacturing solution for biopharmaceutical innovators, and complement our facilities in India to provide global supply solutions.”</p> <p>Sandeep Singh, Chairman of the Board at Enzene and Managing Director of Alkem Laboratories, added, “Enzene has demonstrated that it is committed to providing transformative innovations that can have a positive impact on biopharmaceutical development. In pioneering small-footprint, scalable biomanufacturing, Enzene is providing benefits in sustainability, cost, and ultimately to the global healthcare ecosystem. This latest step in the company’s strategic expansion plans extends Enzene’s commitment to providing equitable access to cost-effective manufacturing for early-stage biologics developers in the U.S. and beyond.”</p> <p>The opening ceremony was also attended by state and local officials, including the Mayor of Hopewell Township, Courtney Peters-Manning, First Lady of New Jersey, Tammy Murphy, and delegates from the offices of Senator Kim and Congresswoman Bonnie Watson Coleman.</p>]]></content:encoded> </item> <item> <title>CN Bio adds computational modelling capabilities to ADME services for enhanced bioavailability profiling</title> <link>https://international-biopharma.com/cn-bio-adds-computational-modelling-capabilities-to-adme-services-for-enhanced-bioavailability-profiling/</link> <dc:creator><![CDATA[Alice Phillips]]></dc:creator> <pubDate>Thu, 04 Sep 2025 15:12:11 +0000</pubDate> <category><![CDATA[news]]></category> <guid isPermaLink="false">https://international-biopharma.com/?p=17975</guid> <description><![CDATA[CN Bio, a leading provider of Organ-on-a-chip (OOC) Systems and solutions that accelerate drug discovery and development workflows, today announced the expansion of its Contract Research Services (CRS) with new PhysioMimix® computational modelling tools. These capabilities have been developed to enhance Absorption, Distribution, Metabolism and Excretion (ADME) profiling for accelerated drug discovery and development workflows. This launch […]]]></description> <content:encoded><![CDATA[<p></p> <ul class="wp-block-list"><li><em>New PhysioMimix in silico tools unlock deeper functional insights from existing assays, advancing translation of MPS data to predict human ADME behavior</em></li> <li><em>End-to-end support from experimental design to data interpretation</em></li></ul> <p></p> <p></p> <p>CN Bio, a leading provider of Organ-on-a-chip (OOC) Systems and solutions that accelerate drug discovery and development workflows, today announced the expansion of its Contract Research Services (CRS) with new PhysioMimix<sup>®</sup> computational modelling tools. These capabilities have been developed to enhance Absorption, Distribution, Metabolism and Excretion (ADME) profiling for accelerated drug discovery and development workflows.</p> <p>This launch represents the Company’s new <em>in silico </em>tools available to customers and is designed to enhance data generation from its range of predictive <em>in vitro </em>tools – unlocking deeper insights into key ADME parameters, including human bioavailability, and enabling more confident <em>in vitro</em> to <em>in vivo</em> extrapolation (IVIVE).</p> <p>CN Bio’s computationaltools combine the insights gained from microphysiological system (MPS) assays with powerful mathematical models. These tools complement the Company’s existing bioavailability assay based on its proprietary dual-organ Gut/Liver model, available via the CRS or as an off-the-shelf kit. The derived data is fully compatible with physiologically-based pharmacokinetic (PBPK) frameworks and can be used to extract additional data from preclinical studies, providing functional predictions of how compounds interact with human biology.</p> <p>By working with CN Bio’s CRS team, customers gain access to broad support and expertise from both MPS and computational modeling specialists. The team collaborates closely with customers throughout the process, from ensuring robust study design to translating experimental data into meaningful ADME predictions. Raw data generated from projects is also translated into an easy-to-interpret format, suitable for supporting go/no go and drug dosing decisions.</p> <p><strong>Dr Yassen Abbas, Lead Scientist, CN Bio, said:</strong> <em>“This year, the FDA made significant changes to phase out animal testing requirements, signaling a clear shift towards the use of more relevant human approaches for preclinical safety and toxicity testing. We are providing the tools to ensure our customers stay ahead of these regulatory changes.” </em><strong>He added:</strong><em> “The launch of our Bioavailability assay last year was a major step towards improving understanding of the appropriate dose regimens for safe and effective new therapies. Now, by integrating advanced in silico modeling into our offering, we are enhancing this service to bridge the in vitro to in vivo translation gap for drug developers. By working with our expert CRS team, customers have access to dedicated support throughout the entire process.”</em></p> <p>For more information on CN Bio’s ADME CRS portfolio, please visit <a href="https://cn-bio.com/in-vitro-services/adme/" target="_blank" rel="noreferrer noopener">https://cn-bio.com/in-vitro-services/adme/</a></p>]]></content:encoded> </item> <item> <title>Eppendorf introduces next generation mechanical pipettes</title> <link>https://international-biopharma.com/eppendorf-introduces-next-generation-mechanical-pipettes/</link> <dc:creator><![CDATA[Alice Phillips]]></dc:creator> <pubDate>Thu, 04 Sep 2025 12:52:15 +0000</pubDate> <category><![CDATA[news]]></category> <guid isPermaLink="false">https://international-biopharma.com/?p=17972</guid> <description><![CDATA[Eppendorf, a leading international life science company that develops, manufactures and distributes instruments, consumables and services for use in laboratories around the world, today announced the commercial launch of the Eppendorf Research 3 neo, designed to deliver accurate and precise results for accelerated volume selection and optimised ergonomics. Following successful release throughout Asia in August, the […]]]></description> <content:encoded><![CDATA[<p></p> <ul class="wp-block-list"><li><em>New Eppendorf Research</em><sup>®</sup><em> 3 neo offers enhanced adaptability, precision, and comfort in pipetting</em></li> <li><em>Pipettes will be showcased in a virtual live launch on Thursday 18<sup>th</sup> September, 10am CEST</em></li></ul> <p></p> <p></p> <p>Eppendorf, a leading international life science company that develops, manufactures and distributes instruments, consumables and services for use in laboratories around the world, today announced the commercial launch of the Eppendorf Research 3 neo, designed to deliver accurate and precise results for accelerated volume selection and optimised ergonomics. Following successful release throughout Asia in August, the Research 3 neo pipettes are now available in both EMEA and the Americas.</p> <p>The durable pipette is highly flexible, allowing users to switch between two volume settings to easily speed up or fine-tune volume changes, combined with a new volume lock feature preventing unintentional volume changes. Further adjustable settings allow the pipette to accommodate different liquid types, tip geometries, reverse pipetting, and altitudes, ensuring optimal accuracy across various applications without the need for recalibration. The use of ColorTag changeable pipette marking rings provides a reversible labelling solution to further increase versatility.</p> <p>Constructed from high-quality materials and subjected to extensive testing, the new mechanical air-cushion pipette delivers high performance, consistently beyond the ISO 8655 test limits when used with epT.I.P.S.<sup>®</sup> pipette tips. With carefully designed ergonomics and customizable accessories, the Research 3 neo offers a well-balanced lightweight design, with low tip attachment and ejection forces to ensure efficient use.</p> <p>Manufactured in an ISO 14001 certified facility powered by renewable energy, the new pipettes reflect Eppendorf’s commitment to sustainability. <a>The Research 3 neo comes in recycled and recyclable packs, and is compatible with BioBased pipette tips made of 100% biobased polypropylene following a mass-balance approach, further reducing environmental impact.</a></p> <p><strong>Christiane Markau, Product Innovation Manager at Eppendorf SE, said: </strong><em>“We are extremely proud to introduce the latest generation of mechanical pipettes, the Research 3 neo. Our mission has been to create a pipette that is the perfect fit for all new users, in terms of its adaptability and accessories, as well as its comfort and performance. This addition to our comprehensive range of tools and instruments provides our customers with a flexible solution to meet all their pipetting requirements.”</em><em></em></p> <p>Eppendorf’s CEO, Dr. Christine Munz, will present the company’s innovation vision and showcase the Eppendorf Research 3 neo pipette during a virtual live launch on Thursday 18<sup>th</sup> September, 10am CEST. For more information and to register, visit<strong>: </strong><a href="https://shorturl.at/zmmm2" target="_blank" rel="noreferrer noopener">https://shorturl.at/zmmm2</a></p> <p>For more information on the Research 3 neo, visit: <a href="http://www.eppendorf.link/best-fit" target="_blank" rel="noreferrer noopener">www.eppendorf.link/best-fit</a></p> <p>For more information on BioBased Consumables, visit: <a href="https://www.eppendorf.com/de-en/lab-academy/lab-solutions/eppendorf-consumables-biobased/" target="_blank" rel="noreferrer noopener">https://www.eppendorf.com/de-en/lab-academy/lab-solutions/eppendorf-consumables-biobased/</a></p>]]></content:encoded> </item> <item> <title>MultiOmic Health and BIO4 Campus Sign MoU to Advance Precision Medicine and Support Bioeconomy Growth in Serbia</title> <link>https://international-biopharma.com/multiomic-health-and-bio4-campus-sign-mou-to-advance-precision-medicine-and-support-bioeconomy-growth-in-serbia/</link> <dc:creator><![CDATA[Alice Phillips]]></dc:creator> <pubDate>Thu, 04 Sep 2025 08:15:22 +0000</pubDate> <category><![CDATA[news]]></category> <guid isPermaLink="false">https://international-biopharma.com/?p=17970</guid> <description><![CDATA[ Sciad Communications / MultiOmic Health Limited (“MOH”), an artificial intelligence (AI)-enabled precision medicine biotechnology company, and BIO4 Campus (“BIO4”), the Republic of Serbia’s flagship biotechnology and life sciences hub, today announced the signing of a Memorandum of Understanding (MoU) to explore collaborative opportunities in biomedicine, biotechnology and bioinformatics, with a strong emphasis on AI applications. BIO4 and MOH will work […]]]></description> <content:encoded><![CDATA[<p></p> <p> <strong><a href="https://email.cisionone.cision.com/c/eJwszkuO8yAQBODTwI4IN-8Fi2x8jaih2wn6_fgHMvH1Rx7N9itVqShDrFZLzlNwPvkELslXpsgGY0CDCyXjeSoWHZhAGEAvVGTLPpZk0lRTYPaPyZUatbFOkxNWj0b8r32pDdvKfShPSyjWV_IqxlT22xXINb_e7_9DmLuAWcB8nudt1IZ0q8cmYD6-u9r5HAJmuTE1VJ1XxsGqUf6Fxx8Ic58sgI6y50_rz7Y3vG7w_lyPgms9tnGNyvHuzNvVn4ojg5qUCdorWxBUgWIVhBqDxoWsj_KT4ScAAP__a7ZZSw" rel="noreferrer noopener" target="_blank">Sciad Communications</a> / </strong><strong><a href="https://email.cisionone.cision.com/c/eJwszUuO6yAQheHVmBlRAWUeAwaZZBtRQZVjdCG-bbuz_pZbPf2Ojn7ONlYEJdmE2Sef7JzUmrGCqxb9wsQM7AIgEboCZjEQiVXLPpbkkqkpiPinmUuN4HAGnieEo7H8a196UOuyH9rzEgr6yl7HmMr7dg2q5_U8_x-Tu0_2MdnH-O5n20art1Won-tkH2oIN9K7dKFDdOP8C88_mNzdoLUQ1Z4_bX-1d6MrL-9X3wr1uo3jVrehjnMXGdfflJkdAWsXwGssZHWxBbUNNQaghdFH9cn2JwAA__93BVaS" rel="noreferrer noopener" target="_blank">MultiOmic Health Limited</a> </strong>(“MOH”), an artificial intelligence (AI)-enabled precision medicine biotechnology company, and <a href="https://email.cisionone.cision.com/c/eJwszU1uAjEMxfHTTHZBzpfjLLJgwzVQHBuIOsO0E8T5K6puf09Pf6meegSj1eWEBYtPxTyqEsVMjAkROKGAY-abCEMM4ByZUZG4hOJ6yap4dYk7QYgJJC0R5hD9Gj92a2PVY1qUW-aIXdASFX6ePoNZ6-P1-p5LOC_-svgLjz2ejrn4i9lURrOHrtqm2iH1D67_sISzi94DmaO-x3Efz9E-VX3e153b2vdtnvq-mfk6VLfP33GS0EBsyIA2cvOWPUfrc6cM7SYRybyr_w0AAP__hepSKA" rel="noreferrer noopener" target="_blank">BIO4 Campus</a> (“BIO4”), the Republic of Serbia’s flagship biotechnology and life sciences hub, today announced the signing of a Memorandum of Understanding (MoU) to explore collaborative opportunities in biomedicine, biotechnology and bioinformatics, with a strong emphasis on AI applications.</p> <p>BIO4 and MOH will work together to foster the growth of Serbia’s bioeconomy ecosystem by identifying and developing opportunities for joint research and innovation. Collaboration will initially focus on cardio-renal-metabolic diseases through integrative medical data and multi-omics approaches (genetics, epigenetics, transcriptomics, proteomics and metabolomics). This research will discover patient endotypes with distinct clinical phenotypes and omics signatures, develop AI-enabled tools to stratify those patient endotypes at earlier disease stages, and identify and validate corresponding patient stratified drug targets. These efforts will enable a more personalised approach to patient care.</p> <p>Insights from this research will enable the joint development of AI-based Software as Medical Device (SaMD) and In Vitro Diagnostic (IVD) products that will optimise patient care pathways using existing treatment options. In parallel, MOH will also devise new superior treatment concepts, generate corresponding drug candidates and conduct clinical trials in partnership with its biopharma industry collaborators.</p> <p>“By joining forces with BIO4 and its network of leading Serbian research and clinical institutions, we see a strong opportunity to advance the development of next-generation precision medicine solutions,” said Robert Thong, CEO of MultiOmic Health. “This collaboration reinforces our commitment to harnessing AI, data science and experimental biology to improve patient outcomes in cardio-renal-metabolic diseases globally.”</p> <p>“BIO4 Campus was created to be a catalyst for Serbia’s bioeconomy and an international hub for innovation,” said Smiljana Krivokuća, CEO of BIO4. “We are delighted to welcome MultiOmic Health as a partner in this mission and look forward to exploring joint opportunities that combine their expertise in precision medicine with our ecosystem’s strengths in biotechnology, clinical research and bioinformatics.”</p>]]></content:encoded> </item> <item> <title>Atelerix and Rodon Global partner to integrate cryo-free preservation technology into specialist logistics solutions</title> <link>https://international-biopharma.com/atelerix-and-rodon-global-partner-to-integrate-cryo-free-preservation-technology-into-specialist-logistics-solutions/</link> <dc:creator><![CDATA[Alice Phillips]]></dc:creator> <pubDate>Wed, 03 Sep 2025 08:31:41 +0000</pubDate> <category><![CDATA[news]]></category> <guid isPermaLink="false">https://international-biopharma.com/?p=17955</guid> <description><![CDATA[Atelerix, a biotech company revolutionising cell preservation and biological transport with its pioneering hydrogel encapsulation technology, today announced an agreement with Rodon Global (“Rodon”), the established freight company focused on clinical trials and drug discovery headquartered in South Africa. The collaboration comes at a pivotal time as Rodon actively expands operations across the United States, […]]]></description> <content:encoded><![CDATA[<p></p> <ul class="wp-block-list"><li><em>Initial agreement to incorporate Atelerix’s non-cryogenic cell preservation technology into international freight and logistics services for drug discovery and clinical trials</em></li> <li><em>Partnership showcased at SACRA (South African Clinical Research Association), Pretoria, 1–2 October 2025</em></li></ul> <p></p> <p>Atelerix, a biotech company revolutionising cell preservation and biological transport with its pioneering hydrogel encapsulation technology, today announced an agreement with Rodon Global (“Rodon”), the established freight company focused on clinical trials and drug discovery headquartered in South Africa. The collaboration comes at a pivotal time as Rodon actively expands operations across the United States, UK, South Africa, and Singapore. By integrating Atelerix’s unique cryo-free preservation products within Rodon’s dynamic logistics offering, the collaboration will significantly broaden access to safe shipping and storage solutions for temperature-sensitive biomaterials, without freezing.</p> <p>Through an initial MoU, Rodon will begin offering Atelerix’s portfolio of hypothermic preservation solutions to customers, providing new options to enhance efficiency across biomedical research and therapeutic development workflows. The mutually-beneficial collaboration grants Atelerix access to a new customer base via a trusted industry partner, whilst enabling Rodon to scale its services through a unique model that addresses traditional challenges in cold-chain logistics. This agreement follows the appointment of MineBio as Atelerix’s exclusive distributor in China<sup>1</sup>, further extending the Company’s global network of logistics partners to deliver a cryo-free, cost-efficient transport solution worldwide.</p> <p>Atelerix’s patented hydrogels directly address cryologistic bottlenecks by stabilising membrane integrity and preserving biological function of cells and other biological substances during transport. Samples can remain in a ready-to-use state at ambient temperatures for up to two weeks, reducing waste and energy consumption, and simplifying shipping and handling protocols. Optimised for whole blood, primary cells, plated cell models, organoids, tissues, and viruses, the technology is applicable across life science and healthcare. It is particularly valuable for cell and gene therapy manufacturing, where it offers a flexible solution for preservation across the full workflow.</p> <p><strong>Alastair Carrington, CEO, Atelerix, commented<em>: </em></strong><em>“The global demand for inexpensive, efficient solutions for storage and transport of biological substances is continually increasing, leading to an urgent unmet need for innovative solutions, which our experienced team of hogs can provide. Working alongside Rodon and our network of global distributors, we are expanding our reach to include the booming South African life science sector, catapulting adoption of our unique technologies in the region, and beyond. We look forward to joining Rodon at SACRA in October to showcase the enormous potential of our collaboration.”</em></p> <p><a><strong>Leonard Neil Lazarus, CEO, Rodon Global, added:</strong></a> <em>“Atelerix’s innovative approach to cell preservation will revolutionise biological transport worldwide, overcoming supply chain challenges associated with temperature sensitive materials, particularly in the drug discovery and clinical research sectors. This partnership represents a significant milestone and differentiator for Rodon, allowing us to overcome these challenges and continue to scale, supporting our life science customers to develop and manufacture novel therapeutics.”</em></p> <ol class="wp-block-list"><li><em>Press Release (16<sup>th</sup> April 2025)</em>: <a href="https://www.atelerix.co.uk/blogs/news/atelerix-signs-exclusive-agreement-with-minebio-to-establish-distribution-channel-for-non-cryogenic-cell-preservation-solutions-in-china" target="_blank" rel="noreferrer noopener">Atelerix signs exclusive agreement with MineBio to establish distribution channel for non-cryogenic cell preservation solutions in China</a></li></ol>]]></content:encoded> </item> </channel></rss> If you would like to create a banner that links to this page (i.e. this validation result), do the following:
Download the "valid RSS" banner.
Upload the image to your own server. (This step is important. Please do not link directly to the image on this server.)
Add this HTML to your page (change the image src attribute if necessary):
If you would like to create a text link instead, here is the URL you can use:
http://www.feedvalidator.org/check.cgi?url=https%3A//international-biopharma.com/feed/
